CureVac CVAC shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of the RNA printer.
Dr. Greune joins the company from Sanofi-Aventis Deutschland, where he held multiple management positions. He served as the General Manager and Vice President of the Cartridges, Devices & Insulin Technology Group.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
At the time of publication, shares of CureVac were trading 12% higher at $75.55. The stock has a 52-week low of $36.15 and a 52-week high of $151.80.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
